InsidersTradesSigma
Oncopeptides AB: insider trades · Finland · FIN-FSA
FI:oncopeptides-abSE0009414576FI·FIN-FSAMcap 653M€Healthcare
Discover the full directors' dealings record of Oncopeptides AB, a listed issuer based in Finland. Shares are listed on FI FI, under the oversight of FIN-FSA. Operating in the Healthcare sector, Oncopeptides AB has logged 6 public disclosures. Market capitalisation: €652.5m. The latest transaction was reported on 18 March 2026 — Purchase. Among the most active insiders: Per Wold-Olsen. The full history is free.
6
Insider Decl.
0
Thresholds
€107,697
6 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
1.71 €
Analyst consensus
1 analystsStrong buy
2.80 €Target 2.80 €(+64%)2.80 €
Income statement
Revenue71.1 M€
Gross profit68.7 M€97% margin
Net income−249.6 M€-350.9% margin
Valuation
PER (forward)17.1x
Beta-1.42
Balance sheet & cash
Market cap652.5 M€
Total debt139.4 M€
Free Cash Flow−222.9 M€
Profitability & ownership
ROA-74.3%
% insiders9.0%
% institutions9.3%
Last declaration on 18 March 2026
Declarations6 total
Executives●Purchase18FIN-FSA
€2,21014,631 shares@ €0.15110.0003% mcap100.0% of flow
Aktie
FI:A003X111-1·
Ideal exit: 12 Dec 2026 (T+270)
Executives●Purchase33FIN-FSA
€20,078140,232 shares@ €0.14320.0031% mcap100.0% of flow
BTA (betald tecknad aktie)
FI:A003X096-1·
Ideal exit: 11 Dec 2026 (T+270)
Executives●Purchase25FIN-FSA
€60,354418,876 shares@ €0.14410.0092% mcap72.2% of flow
BTA (betald tecknad aktie)
FI:A003X103-1·
Ideal exit: 12 Dec 2026 (T+270)
Executives●Purchase13FIN-FSA
€23,25179,590 shares@ €0.29210.0036% mcap27.8% of flow
BTA (betald tecknad aktie)
FI:A003S333-1·
Ideal exit: 13 Jun 2026 (T+270)
Executives●Purchase12FIN-FSA
€4291,000 shares@ €0.42890.0001% mcap23.8% of flow
Aktie
FI:A003R768-1·
Ideal exit: 23 May 2026 (T+270)
Executives●Purchase18FIN-FSA
€1,3753,500 shares@ €0.39290.0002% mcap76.2% of flow
Aktie
FI:A003R706-1·
Ideal exit: 22 May 2026 (T+270)
6 of 6 declarations